• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

锂盐在重度甲状腺功能亢进症的治疗中有一席之地吗?(作者译)

[Do lithium salts have a place in the treatment of severe hyperthyroidism? (author's transl)].

作者信息

Eulry F, Orgiazzi J, Mornex R

出版信息

Nouv Presse Med. 1977 Oct 8;6(33):2955-8.

PMID:593831
Abstract

In a patient with hyperthyroidism resulting in cachexia, severe cardiac complications and functional renal failure, and a second case of hyperthyroidism refractory to carbimazole as a result of iodine overload, the administration of 1 to 3 g of lithium gluconate every 1 to 3 days, in association with carbimazole, led to persistent clinical and biological improvement in 8 to 16 days. In the first case, the course was complicated by neurological intolerance (blood lithium 0.98 mEq/l) which responded to the temporary interruption of treatment and by a transient escape of thyroid function from the effects of lithium which disappeared after a slight adjustment in the dose. In the second case, the course under treatment was favourable from the outset. Thus in forms of hyperthyroidism in which usual forms of treatment are inadequate and where there is a risk of "acute crises", lithium may be valuable as adjuvant therapy. If the dose is regularly modified in order to obtain a daily blood lithium level of less than 0.60 mEq/l, and on condition of close clinical, electrocardiographic and ionic surveillance, cardiac and renal failure and neuropsychiatric disturbances do not prevent the use of lithium, which the authors feel to be of irreplaceable value.

摘要

在一名因甲状腺功能亢进导致恶病质、严重心脏并发症和功能性肾衰竭的患者以及另一名因碘过载而对卡比马唑难治的甲状腺功能亢进患者中,每1至3天给予1至3克葡萄糖酸锂,并联合卡比马唑治疗,在8至16天内使临床和生物学指标持续改善。在第一例患者中,治疗过程因神经耐受性问题(血锂浓度0.98 mEq/l)而复杂化,该问题通过暂时中断治疗得到缓解,还因甲状腺功能对锂的作用出现短暂逃逸,在轻微调整剂量后消失。在第二例患者中,治疗过程从一开始就很顺利。因此,在常规治疗方法不足且存在“急性危机”风险的甲状腺功能亢进形式中,锂作为辅助治疗可能具有重要价值。如果为了使每日血锂水平低于0.60 mEq/l而定期调整剂量,并在密切的临床、心电图和离子监测的条件下,心力衰竭、肾衰竭和神经精神障碍并不妨碍使用锂,作者认为锂具有不可替代的价值。

相似文献

1
[Do lithium salts have a place in the treatment of severe hyperthyroidism? (author's transl)].锂盐在重度甲状腺功能亢进症的治疗中有一席之地吗?(作者译)
Nouv Presse Med. 1977 Oct 8;6(33):2955-8.
2
[Lithium therapy of thyrotoxicosis. Clinical experiences and results with a new therapeutic principle].[甲状腺毒症的锂盐治疗。一种新治疗原则的临床经验与结果]
Dtsch Med Wochenschr. 1973 Aug 24;98(34):1551-4. doi: 10.1055/s-0028-1107079.
3
[Results of lithium treatment in severe hyperthyroidism].[锂治疗重度甲状腺功能亢进症的结果]
Dtsch Z Verdau Stoffwechselkr. 1984;44(1):26-31.
4
Effect of short-term lithium carbonate administration in hyperthyroidism, with or without associated ophthalmopathy.短期服用碳酸锂对伴有或不伴有相关眼病的甲状腺功能亢进症的影响。
Endocrinologie. 1986 Apr-Jun;24(2):109-13.
5
[Transdermal carbimazole for the treatment of feline hyperthyroidism].[用于治疗猫甲状腺功能亢进的透皮卡比马唑]
Tijdschr Diergeneeskd. 2006 Jul 1;131(13):478-82.
6
Successful management of Graves' disease in a patient undergoing regular dialysis therapy.
Arch Intern Med. 1985 Feb;145(2):337-9.
7
[First experiences with short-term lithium therapy in severe thyrotoxicosis].[重度甲状腺毒症短期锂治疗的初步经验]
Z Gesamte Inn Med. 1981 Oct 1;36(19):704-7.
8
[Hypercalcemia as first manifestation of thyrotoxicosis (author's transl)].高钙血症作为甲状腺毒症的首发表现(作者译)
Med Clin (Barc). 1980 Feb 10;74(3):107-8.
9
[Effects of chronic administration of lithium on thyroxine (T4), triiodothyronine (T3), reverse T3 (rT3) free thyroxine ratio (FTR) and thyreostimuline (TSH) in thyrotoxicosis (author's transl)].慢性给予锂对甲状腺毒症患者甲状腺素(T4)、三碘甲状腺原氨酸(T3)、反三碘甲状腺原氨酸(rT3)、游离甲状腺素比值(FTR)及促甲状腺素(TSH)的影响(作者译)
Sem Hop. 1981;57(25-28):1202-5.
10
An evaluation of lithium as an adjunct to carbimazole treatment in acute thyrotoxicosis.锂作为卡比马唑治疗急性甲状腺毒症辅助药物的评估。
Acta Endocrinol (Copenh). 1976 Sep;83(1):86-92. doi: 10.1530/acta.0.0830086.